Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
|Videos|August 8, 2022
Dr. Syan on new recharge-free sacral neuromodulation system for bladder/bowel dysfunction
Author(s)Urology Times staff
Advertisement
In this video, Raveen Syan, MD, discusses Axonics F15, an
Advertisement
Related to this article
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Survey: Service members and veterans with NMIBC report barriers to treatment access
3
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
4
BCG-naïve NMIBC: Optimizing initial treatment selection
5